Balanced news tone
News Sentiment
ARGX sentiment intelligence
argenx SE news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
56
Balanced news tone
19 relevant articles
News tone and price action are not far from neutral.
84/100 classification confidence.
directly relevant articles
high-authority source matches
-1.3% over one week, +10.4% over four weeks, trend inactive, and materially above fair value.
argenx (ARGX) 46th Annual William Blair Growth Stock Conference Summary
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Primary event
Market update
84/100 classification
One-week reaction
-1.3%
Price digesting
Trend fit
Trend inactive
10.4% over four weeks
Fair value
45.7%
Materially above fair value
Sentiment Mix
Positive, neutral, negative
Positive
6
Neutral
13
Negative
0
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
Quartr
Direct company coverage
argenx (ARGX) 46th Annual William Blair Growth Stock Conference Summary
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 19 Jun 2026 19:25
- Source
- Quartr
The Globe and Mail
Direct company coverage
Wells Fargo Keeps Their Buy Rating on Argenx Se (ARGX)
- Tone
- Positive 66/100
- Event
- Analyst action
- Published
- 18 Jun 2026 11:54
- Source
- The Globe and Mail
AD HOC NEWS
Direct company coverage
Argenx SE Stock (NL0010832176): Earnings Snapshot And Valuation Focus After Recent Results
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 16 Jun 2026 19:45
- Source
- AD HOC NEWS
AD HOC NEWS
Direct company coverage
Argenx SE Stock (NL0010832176): Biotech name in focus amid sector moves and analyst attention
- Tone
- Neutral 50/100
- Event
- Analyst action
- Published
- 15 Jun 2026 14:59
- Source
- AD HOC NEWS
simplywall.st
Direct company coverage
Argenx (ENXTBR:ARGX) Stock Valuation After Expanded FDA Approval For Vyvgart And Pipeline Progress
- Tone
- Neutral 50/100
- Event
- Regulatory and legal
- Published
- 13 Jun 2026 11:03
- Source
- simplywall.st
Market source
Direct company coverage
Assessing argenx (ENXTBR:ARGX) Valuation After Strong Recent Share Price Momentum
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 10 Jun 2026 07:00
- Source
- Market source
Market source
Direct company coverage
Argenx (ARGX) Soars 5.8%: Is Further Upside Left in the Stock?
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 08 Jun 2026 07:00
- Source
- Market source
AD HOC NEWS
Direct company coverage
Argenx SE stock (NL0010832176): shares trade quietly as investors focus on latest quarterly update a
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 08 Jun 2026 07:00
- Source
- AD HOC NEWS
AD HOC NEWS
Direct company coverage
Argenx SE stock (NL0010832176): Fokus auf Zulassungsnews und Markterweiterung nach jüngsten Updates
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 28 May 2026 07:00
- Source
- AD HOC NEWS
AD HOC NEWS
Direct company coverage
Argenx SE stock (NL0010832176): Focus shifts to chronic ITP data and efgartigimod ramp-up
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 May 2026 07:00
- Source
- AD HOC NEWS
AD HOC NEWS
Direct company coverage
Argenx SE stock (NL0010832176): autoimmune drug specialist in focus after latest Vyvgart update
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 20 May 2026 07:00
- Source
- AD HOC NEWS
AD HOC NEWS
Direct company coverage
Argenx SE stock (NL0010832176): Biotech stock moves on latest clinical data readout and commercial p
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 09 May 2026 07:00
- Source
- AD HOC NEWS
AD HOC NEWS
Direct company coverage
Argenx SE stock (NL0010832176): Biotech firm eyes growth in autoimmune therapies
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 08 May 2026 07:00
- Source
- AD HOC NEWS
Market source
Direct company coverage
Argenx (ARGX) tops earnings expectations despite slight revenue shortfall
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 07 May 2026 07:00
- Source
- Market source
Market source
Direct company coverage
Here’s Why Argenx SE (ARGX) Slipped in Q1
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 04 May 2026 07:00
- Source
- Market source
Market source
Direct company coverage
Argenx (ARGX) Outlook Improves on Autoimmune Pipeline Expansion
- Tone
- Positive 66/100
- Event
- Guidance
- Published
- 02 May 2026 07:00
- Source
- Market source
Market source
Direct company coverage
Analysts Express Mixed Opinion on Argenx SE (ARGX) Stock
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 08 Mar 2026 08:00
- Source
- Market source
Market source
Direct company coverage
Why Argenx SE (ARGX) Stock Advanced on Commercial Execution
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 Jan 2026 08:00
- Source
- Market source
GuruFocus
Direct company coverage
argenx SE (XBRU:ARGX) Stock Price, Trades & News
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 22 Apr 2019 12:16
- Source
- GuruFocus